Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Active not recruiting 5Recruiting 4Not yet recruiting 2Completed 2Terminated 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1

Conditions

Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Adenocarcinoma Of Esophagus 1

Interventions

Specimen Handling 21Magnetic Resonance Spectroscopy 17Carboplatin 16Gemcitabine 14pembrolizumab 11Paclitaxel 11Cisplatin 11Interviews as Topic 10Injections 10fludarabine 9Radiotherapy 8Oxaliplatin 8Nivolumab 8Dexamethasone 8Cyclophosphamide 8Irinotecan 7Fluorouracil 7Bortezomib 7Biopsy 7Bevacizumab 7toripalimab 6Radiosurgery 5Pemetrexed 5Leucovorin 5Capecitabine 5130-nm albumin-bound paclitaxel 5trastuzumab deruxtecan 4liposomal doxorubicin 4cemiplimab 4X-Rays 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Not yet recruiting × Ramucirumab × 30 days × Clear all
NCT07603856 2026-05-22

REVIVE

University of Chicago

Phase 2 Not yet recruiting
39 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07594548 2026-05-18

Futibatinib With Paclitaxel and Ramucirumab for the Treatment of Locally Advanced or Unresectable Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

Northwestern University

Phase 1 Not yet recruiting
18 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus

Data powered by HemOnc (CC BY 4.0) Colophon âš¡